Lenzilumab

Summary

Lenzilumab (CHEMBL3707325) is a phase-3 clinical-stage antibody; indicated across 6 conditions including pneumonia and severe acute respiratory syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 6 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707325
Name	Lenzilumab
Type	Antibody
Max phase	3

Also known as: KB-003, KB003, Lenzilumab, LENZILUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
asthma	2	MONDO:0004979	MONDO:0004979
neoplasm of mature B-cells	1	MONDO:0004949	EFO:0000096
chronic myelomonocytic leukemia	1	MONDO:0020311	EFO:1001779

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04351152	PHASE3	UNKNOWN	Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
NCT04534725	PHASE3	COMPLETED	COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
NCT00995449	PHASE2	TERMINATED	Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis
NCT04583969	PHASE2	COMPLETED	ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
NCT02546284	PHASE1	COMPLETED	Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
NCT04314843	PHASE1	TERMINATED	Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).